Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month. PhRMA and its member companies appreciate Commissioner Hamburg’s years of dedication to health care innovation that helps America’s patients.
Most Recent Posts
By Jennifer Bryant
According to a new report from actuaries Gabriela Dieguez, Bruce Pyenson and Jennifer Carioto, at Milliman, major pharmacy benefits managers (PBMs) often overestimate future spending on specialty medicines, sometimes by nearly 10 percentage points.
When a Medicare Part D beneficiary adheres to their prescription regimen, both the individual and the broader health care system benefit. The Congressional Budget Office (CBO), for example, now estimates increasing the number of Part D prescriptions filled by just 1 percent reduces program spending on medical services by approximately 0.20 percent. The cost savings are even greater for seniors with certain chronic conditions. Today, we’re looking at congestive heart failure.
In recent years, the development of new medicines has helped transform the lives of patients. But lives cannot be improved without access to those innovative treatments. We support helping patients get access to what they need to live happier, healthier lives, and it was our focus this week.
Did you know health insurance exchange plans are allowed to drop coverage of medications from their formularies midyear? Early evidence indicates that some health insurance exchange or marketplace plans are taking advantage of this flexibility and significantly reducing access to needed medications.
By Anne Pritchett, PhD
As we enter the second half of the decade, the biopharmaceutical industry’s approach to research and development (R&D) continues to evolve to meet the growing demand for new medicines.
Today is World Cancer Day, and 2015’s “Not beyond us” theme highlights an incredibly important message: we’re making tremendous advances in the fight against cancer and continued progress means a future with a cure could be right around the corner. America’s biopharmaceutical research companies are dedicated to achieving this outcome and improving the quality of patients’ lives through pioneering medicines and enabling access to those treatments.
Research and development (R&D) is the backbone of the biopharmaceutical industry and the reason why we have seen more than 450 new medicines approved in the U.S.
Medicare Part D is an incredibly important and successful program that provides seniors and persons with disabilities with access to affordable prescription drug coverage. While recent surveys indicating about 90 percent of beneficiaries are satisfied with their Part D coverage, you may not know about all the ways Medicare provides value to beneficiaries.
For the biopharmaceutical industry, patient well-being is at the center of everything we do. In keeping patients at the forefront, we are doing all that we can to help people live longer, healthier lives. This week, we highlighted just a few ways we are working to translate that commitment into tangible outcomes.
Many people likely don’t realize that the human papillomavirus, or HPV, is one of the most prevalent sexually transmitted diseases in the United States. This means 79 million Americans, both men and women, currently carry the virus, which in some cases can lead to cervical cancer.
While the Affordable Care Act (ACA) expanded access to health insurance coverage for millions, a new study from the Harvard T.H. Chan School of Public Health reveals that insurers may be discriminating against patients through the drug benefit design of Essential Health Benefit plans.
Since the publication of this post, the Alzheimer’s Association released a new report, “Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars,” that examines the potential lives saved and economic impact if a treatment is discovered that delays the onset of Alzheimer’s disease by 2025. Key findings of the report include:
As someone who grew up around the biopharmaceutical industry and knows firsthand the impact that it has on local communities, I’m frequently reminded of our members’ far-reaching impact in my role as liaison between PhRMA and the Pharmaceutical Industry Labor-Management Association.
Although we are not even a month into 2015, the U.S. trade agenda has already taken center stage and this coming week will prove to be no different. Less than 24 hours after returning from his trip to India with President Obama to further advance our trading relationship there, United States Trade Representative Michael Froman testified before both the U.S.